BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
NCT01441297
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
OTHER_GOV
Sponsor class
Conditions
Small Cell Lung Cancer
Small Cell Lung Cancer Recurrent
Interventions
DRUG:
BIBF 1120
Sponsor
Ji-youn Han
Collaborators
[object Object]